Skip to content
Biotechnology

BioMed X Launches a New Call for Application in Autoimmune Disease Research

The BioMed X Institute 3 mins read

A new research team at the BioMed X Institute will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.

HEIDELBERG, GERMANY / ACCESSWIRE / November 7, 2023 / BioMed X, an independent biomedical research institute, announced yesterday the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune disease.

Current therapeutic strategies for autoimmune diseases primarily focus on broadly suppressing the immune response, with significant side effects. More importantly, none of these treatments address one of the root causes of the disease, the autoreactive plasma cells that produce antibodies targeting self-antigens. By exploring the deep biology of human autoreactive plasma cells to identify biomarkers that distinguish them from their physiological counterparts, this project aims to identify new therapeutic strategies to selectively eliminate these cells in patients suffering from autoimmune diseases.

"Immunology - including autoimmunity - is one of our R&D focus areas at our BioMed X Institutes in Heidelberg, New Haven, and our XSeed Labs in Ridgefield. Currently, we are hosting five immunology research teams at different stages of development. We are excited to extend our immunology research capabilities with this new project in the field of autoreactive plasma cells," explains Christian Tidona, Founder and Managing Director of the BioMed X Institute.

This new research group will be located at the BioMed X Institute in Heidelberg, Germany. Each BioMed X project is a collaboration with a leading pharmaceutical company. To learn more about this project and how to apply, visit the BioMed X Career Space at https://career.bio.mx/call/2023-BMX-C02. The deadline for applying is January 7, 2023.

About BioMed X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information:

Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706

Related Images

SOURCE: BioMed X Institute

.


View source version on accesswire.com:
https://www.accesswire.com/800139/biomed-x-launches-a-new-call-for-application-in-autoimmune-disease-research

More from this category

  • Biotechnology, Business Company News
  • 24/07/2024
  • 10:53
Jane Morgan Management

LTR Pharma Ltd (ASX:LTP) Completes A$10.5 million Placement to Expedite Commercialisation of SPONTAN

Sydney, Australia – 24 July 2024 – LTR Pharma Limited (ASX: LTP) ("LTR Pharma" or "the Company"), a company focused on improving men’s health through the clinical development and commercialisation of an innovative nasal spray treatment for Erectile Dysfunction ("ED") called SPONTAN®, is pleased to announce the successful completion of a A$10.5 million share placement to sophisticated and new institutional investors. The placement received demand significantly above the A$10.5 million raised. Key Highlights: Successful Fundraising: LTR Pharma has raised A$10.5 million through a private placement at an issue price of A$0.73 per share, representing a 13.2% discount to the 30-day…

  • Contains:
  • Agriculture Farming Rural, Biotechnology
  • 23/07/2024
  • 15:56
La Trobe University

Nation’s food security tackled through new institute

La Trobe University is paving the way for Australian food security, with the establishment of a new institute that will expand cutting-edge agricultural research and innovation. The La Trobe Institute for Sustainable Agriculture and Food (LISAF) officially launched today (23 July), to undertake research and innovation across the agri-food-health chain, aiming to enhance profitability for producers while also improving product quality and choice for consumers. LISAF Director Professor Tony Bacic said a key component of the Institute’s “paddock to gut” research was to enhance plant functionality, enabling food and medicinal crops to be grown in innovative ways and with new…

  • Biotechnology, Medical Health Aged Care
  • 22/07/2024
  • 12:56
Illumina

Research into psychedelic medicines to treat anxiety wins ANS Illumina Neurogenomics Award 2024

Genomic technologies to discover biological markers, within the blood, that could predict patient response to psychedelic medicines such as psilocybin. MELBOURNE, AUSTRALIA, 22 July 2024 - Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the winner of the annual Australasian Neuroscience Society (ANS) Illumina Neurogenomics Research Award as Dr Andrew Gibbons from the Department of Psychiatry, School of Clinical Sciences at Monash Health. “Psilocybin, a chemical produced by hallucinogenic mushrooms, is a psychedelic medicine that has shown to meaningfully reduce symptoms of generalized anxiety during psychotherapy for patients. However, not all patients respond.…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.